Keytruda (pembrolizumab) has transformed cancer treatment in the UK, offering a powerful immunotherapy option for patients with melanoma, lung cancer, Hodgkin lymphoma, stomach cancer, and urothelial carcinoma. By harnessing the immune system to attack cancer cells, Keytruda has improved survival rates and quality of life for many patients. As the incidence of cancer rises and immunotherapy becomes more established, the UK Keytruda Market is expanding steadily, driven by clinical demand and regulatory support.

The UK Keytruda Market was valued at approximately USD 2.22 billion in 2025 and is projected to reach USD 5.32 billion by 2035, growing at a CAGR of 9.14%. This growth reflects rising cancer incidence—cancer cases in the UK have increased by approximately 5% annually—and growing adoption of immunotherapy. Lung cancer represents the largest cancer type segment, valued between USD 800 million and USD 2.2 billion in 2024, followed by melanoma, urothelial carcinoma, Hodgkin lymphoma, and stomach cancer.

The National Health Service (NHS) has been pivotal in facilitating access to Keytruda, ensuring eligible patients receive timely treatment. Ongoing clinical trials and research initiatives are expanding the drug's applications, with new indications and combination therapies under investigation. As the UK continues to prioritize cancer care and as immunotherapy becomes more established, the UK Keytruda Market is positioned for sustained growth, with lung cancer and melanoma leading demand.

People Also Ask

• What is Keytruda?
  Keytruda (pembrolizumab) is an immunotherapy drug used to treat several types of cancer, including melanoma, lung cancer, and Hodgkin lymphoma.

• Why is the UK Keytruda market growing?
  Growth is driven by rising cancer incidence, increasing adoption of immunotherapy, and regulatory support from the NHS and MHRA.

Tags: #Keytruda #Immunotherapy #UKHealthcare #CancerTreatment #Oncology #Pembrolizumab